TEVA-INDOMETHACIN 50 MG
INDOMETHACIN : 50 MG · DIN 00337439 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-INDOMETHACIN?
TEVA-INDOMETHACIN 50 MG contains INDOMETHACIN : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 00337439, held by TEVA CANADA LIMITED, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 14-Jul-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-INDOMETHACIN used for?
Symptomatic treatment of Rheumatoid Arthritis, Ankylosing (Rheumatoid) Spondylitis, Osteoarthritis, Degenerative Joint Disease of the Hip, and Acute Gout.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00337439 |
|---|---|
| Brand name | TEVA-INDOMETHACIN |
| Generic / active ingredient | INDOMETHACIN : 50 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 50 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | M01AB01 INDOMETACIN |
| AHFS class | 28:08.04.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 14-Jul-2015 |
| Original market date | 1980-12-31 00:00:00 |
How is it administered?
Initial: 25 mg 2-3 times/day. Increase by 25 mg weekly if needed to max 150-200 mg/day. Gout: 50 mg 3 times/day. Take with food or antacids. Use lowest effective dose for shortest duration.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (section 11 mentioned in TOC but text cuts off). Standard practice: Store at 15-30°C.
How is it supplied?
Bottles of 100, 500 and 1000 capsules.
Contraindications
CABG surgery; 3rd trimester pregnancy; breastfeeding; severe heart failure; hypersensitivity to indomethacin/ASA/NSAIDs; active GI ulcer/bleeding; bleeding disorders; IBD; severe liver/renal impairment.
Warnings and precautions
Serious CV risk (MI, stroke); GI toxicity (bleeding, ulceration); CNS effects (headache, dizziness); may mask infection; risk of hypertension and fluid retention.
What can be used instead?
Other Canadian products sharing ATC code M01AB01 INDOMETACIN. 7 of 31 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-INDOMETHACIN | 50 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02499223 |
| MINT-INDOMETHACIN | 25 MG | CAPSULE | MINT PHARMACEUTICALS INC | MARKETED | DIN 02461811 |
| MINT-INDOMETHACIN | 50 MG | CAPSULE | MINT PHARMACEUTICALS INC | MARKETED | DIN 02461536 |
| ODAN-INDOMETHACIN | 100 MG | SUPPOSITORY | ODAN LABORATORIES LTD | MARKETED | DIN 02231800 |
| ODAN-INDOMETHACIN | 50 MG | SUPPOSITORY | ODAN LABORATORIES LTD | MARKETED | DIN 02231799 |
| TEVA-INDOMETHACIN | 25 MG | CAPSULE | TEVA CANADA LIMITED | MARKETED | DIN 00337420 |
| APO-INDOMETHACIN | 25 MG | CAPSULE | APOTEX INC | DORMANT | DIN 00611158 |
| APO-INDOMETHACIN | 50 MG | CAPSULE | APOTEX INC | DORMANT | DIN 00611166 |
| FTP-INDOMETHACIN | 25 MG | CAPSULE | FTP-PHARMACAL INC. | CANCELLED POST MARKET | DIN 02238442 |
| FTP-INDOMETHACIN | 50 MG | CAPSULE | FTP-PHARMACAL INC. | CANCELLED POST MARKET | DIN 02238443 |
Who else supplies INDOMETACIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. INDOMETACIN appears in 74 registered pack listings across 9 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.